Press Release **For Immediate Dissemination**

Glenmark's Consolidated Revenue increases by 10.62% to Rs. 66447.68 Mn in FY 14-15

Consolidated Revenue in Q4 FY14-15 was Rs. 17758.13 Mn an increase of 4.24%

Business Highlights

- India Business grew at 15.03% to Rs. 4405.71 Mn for the quarter and to Rs. 17489.53 Mn for the year
- US Business grew by 7.09% to Rs. 5363.44 Mn for the quarter and to Rs. 20397.66 Mn for the year
- Europe Business grew by 25.93% to Rs. 2433.00 Mn for the quarter and to Rs. 6445.33 Mn for the year
- Latin America Business grew by 70.51% to Rs. 1810.35 Mn for the quarter and to Rs. 7640.00 Mn for the year

Mumbai, May 29, 2015: Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical company today announced its results for the fourth quarter and year ended March, 31, 2015.

For the fourth quarter ended March 31, 2015, Glenmark's consolidated revenue was at Rs. 17,758.13 Mn (USD 285.38 Mn) as against Rs. 17035.60 Mn (USD 276.86 Mn). For the year ended March 31, 2015, Glenmark's consolidated revenue was at Rs. 66,447.68 (USD 1086.19 Mn) as against Rs. 60,069.35 (USD 994.09 Mn) recording an increase of 10.62%.

Consolidated Net Profit was at Rs. 106.13 Mn for the Quarter and Rs. 4753.10 Mn for the year ended March, 31, 2015.

**The Net Profit is not comparable due to exceptional item of Rs. 1870.89 Mn in the fourth quarter on account of the settlement claim including legal expenses arrived with the State of Texas by Glenmark Generics Inc., USA an ultimate subsidiary of Glenmark Pharmaceuticals Ltd.*

"We continue to record good growth in our India, LatAm and Europe businesses. Currency devaluation and subdued business environment persisted to impact our Rest of the World, especially Russian operations. We have been also making steady progress in our innovation pipeline with our 3 NCE and 4 NBE molecules in development;" **said Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals Limited.**

The Board of Directors recommend a final dividend of 200 % i.e. Rs. 2 per equity share of the face value of Re. 1 each for FY 2015.

India

Sales for the formulation business in India for the fourth quarter ended March 31, 2015, was at Rs. 4405.71 Mn (USD 70.71 Mn) as against Rs. 3,829.96 Mn (USD 62.05 Mn) in the previous corresponding quarter, recording a growth of 15.03%.

USA Formulations

Glenmark Pharmaceuticals Inc., U.S.A. registered revenue from the sale of finished dosage formulations was at Rs. 5,363.44 Mn (USD 86.16 Mn) for the quarter ended March 31, 2015 against revenue of Rs. 5,008.52 Mn (USD 81.09 Mn) for the previous corresponding quarter, recording an increase of 7.09%.

Africa, Asia and CIS Region (ROW)

For the fourth quarter, revenue from Africa, Asia and CIS region was Rs. 2198.41 Mn (USD 35.34 Mn) as against Rs. 3,425.34 Mn (USD 55.93 Mn) for the previous corresponding quarter.

Europe Formulations

Glenmark Europe's operations revenue for the fourth quarter ended March 31, 2015 was at Rs. 2,433.00 Mn (USD 39.37 Mn) as against Rs. 1,932.00 Mn (USD 31.60 Mn) recording growth of 25.93%.

Latin America

Glenmark's revenue from its Latin American and Caribbean operations was at Rs. 1,810.35 Mn (USD 29.00 Mn) for the fourth quarter ended March 31, 2015 as against Rs. 1,061.74 Mn (USD 17.22 Mn), recording an increase of 70.51%.

Active Pharmaceutical Ingredients (API)

Revenue from sale of API to regulated and semi-regulated markets globally was Rs. 1,547.22 Mn (USD 24.84 Mn), for the quarter ended March 31, 2015 against Rs. 1,530.63 Mn (USD 24.88 Mn) for the previous corresponding quarter.

About Glenmark

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues. (SCRIP 100 Rankings published in the year 2014). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.] and Pain [neuropathic pain and inflammatory pain].

The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has 14 manufacturing facilities in four countries and has six R&D centers. The Generics business of Glenmark services the requirements of the US and Western Europe markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.

For further information, please contact:
Jason D'Souza / Rajdeep Barooah
Glenmark, Mumbai, India
Tel: [+91 22] 40189919/984
Email: corpcomm@glenmarkpharma.com